N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=22 Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Menopause · Fracture · Osteoporosis
Primary: Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA) — 10.8 percentage of BMD change
N/A N=82 IGF-1 and Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03
Phase 4 N=53 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
Phase 3 N=77 Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa
Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001
Phase 3 N=30 Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study
Bone Density · Bone Loss · Anorexia Nervosa
Primary: Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA) — 0.90; 0.87 g/cm^2 — p=0.009
N/A N=94 Bone Health in Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy
Primary: Bone Mineral Density in FSHD — -0.4 z-score
Phase 2 N=112 A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Osteogenesis Imperfecta, Type I · Osteogenesis Imperfecta Type III · Osteogenesis Imperfecta Type IV
Primary: Change From Baseline in Radial Trabecular Volumetric Bone Mineral Density (Tr vBMD) at Month 12 — 1.004; 0.993; 0.992 ratio — p=0.644
N/A N=1,011 Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX
Osteoporosis
Primary: Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis — 93.7; 100 percentage of true positives
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
Phase 4 N=69 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
Osteoporosis
Primary: Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies — 12.43; -2.51…
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Phase 3 N=30 Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
Bone Density, Low · Bone Loss · Anorexia Nervosa
Primary: Percent Change From Baseline to 12 Months in Postero-anterior Lumbar Spine Bone Mineral Density by Dual Energy X-ray Absorptiometry (DXA). — 12.4; -0.3 % change…
Phase 3 N=135 The Effect Of Oral Ibandronate In Male Osteoporosis
Male Osteoporosis
Primary: Mean Percent Change in BMD of the Lumbar Spine From Baseline to Month 12 — .94; 3.52 percent — p=<0.001
Phase 2 N=15 A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
Low Bone Mass · Low Bone Mineral Density · Osteoporosis
Primary: Number of Participants With Normal/Abnormal Bone Histology — 15; 15; 15; 0 Participants
Phase 2 N=23 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01
Phase 2 N=399 A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)
Osteoporosis
Primary: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months — -0.13; -0.62; 1.50; 2.65 Percentage change — p=<=0.001
N/A N=2,684 A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Osteoporosis
Primary: Number of Participants That Initiate an Osteoporosis Prescription Medication — 157; 153 Participants
Phase 2 N=247 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
Postmenopausal Osteoporosis
Primary: Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12 — 2.4; 3.4; -.8 Percent Change from Baseline
N/A N=11 Alendronate in Juvenile Osteoporosis
Juvenile Osteoporosis · Low Bone Density · Fractures
Primary: Bone Mineral Density (BMD) of the Lumbar Spine (Participants With Percentage Increase). — 11 participants
N/A N=142 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Differentiated Thyroid Cancer · Osteoporosis
Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change
Phase 3 N=200 An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density
Primary: Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8 — 8.4; 11.2; 11.0; 16.5 percent
Phase 2 N=419 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density · Postmenopausal Osteoporosis
Primary: Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine — -0.1; 4.1; 7.1; 5.4 percent change — p=< 0.0001
Phase 2 N=21 Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Bone Metabolism — 34.3; 10.4 ng/ml
Phase 4 N=356 A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
Post Menopausal Osteoporosis
Primary: Percentage of Participants Who Preferred Ibandronate Monthly Dosing to Risedronate Weekly Dosing — 81.7; 78.2; 79.9 percentage of participants — p=<0.0001
Phase 3 N=79 A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
Low Bone Mass · Low Bone Mineral Density · Osteoporosis
Primary: Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT — -5.5; -1.8 Percent change — p=0.0766
Phase 2 N=154 A Study of LY2541546 in Women With Low Bone Mineral Density
Osteoporosis
Primary: Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.065; 0.115; 0.142; 0.054 g/cm^2
Phase 2 N=41 Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
Adult Idiopathic Generalized Osteoporosis
Primary: Change in Lumbar Spine Bone Mineral Density (LS-BMD) on Active Medication — 10.1; 4.1 percentage of change
Phase 1 N=19 Melatonin Osteoporosis Prevention Study
Osteoporosis · Osteopenia
Primary: The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline — -0.6; 1.83 ng/mL
N/A N=36 Texture Analysis for Postmenopausal Osteoporosis
Osteoporosis · Osteopenia
Primary: Changes in Lumbar Spine BMD +/- Treatment With Alendronate — 5.28; -1.48 Percent Change